Protagonist Therapeutics Inc.
Discovering oral anti-inflammatory peptide therapeutics
This article was originally published in Start Up
It takes one to know one. That’s the road that Protagonist Therapeutics Inc. has taken in forging alliances with other small companies focused on developing peptide therapeutics, instead of taking the more conventional step of signing a Big Pharma partner. Protagonist has found that smaller firms understand the value of its platform and what it can deliver. Protagonist’s platform revolves around disulfide-rich peptides, a specific subclass of peptides whose molecular structure makes them unusually stable. That characteristic lowers their susceptibility to enzymatic degradation and therefore boosts the potential that they can become oral drugs. Advocates see DRPs as combining the best aspects of both proteins and small molecules: physically large enough to suitably cover the surfaces of important molecular targets now bound only by injectable proteins, yet small enough to have pharmacokinetic properties similar to small molecules.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.